FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978889724> ?p ?o ?g. }

• W2978889724 endingPage "v441" @default.
• W2978889724 startingPage "v441" @default.
• W2978889724 abstract "Abstract Background We investigated the safety and efficacy of bendamustine-rituximab (BR) in previously untreated symptomatic and advanced CLL patients, as there is no data available on BR from Indian subcontinent. Methods This retrospective study included 120 consecutive treatment naive patients with CLL without del (17p), who were registered at Department of Medical Oncology, AIIMS between January 2010 and to July 2018. Bendamustine was given at a dose of 90 mg/m2on day 1 and 2, combined with rituximab 375 mg/m2 rituximab on day 1, every 28 days for up to 6 courses. Event free survival (EFS) was defined as date of treatment to date of relapse, disease progression or death due to any cause. Results The median age was 57 years (range: 30-75 years). As per clinical Rai stage 30(25%) patients were in stage II, 42(35%) were in stage III and 48(40%)were in stage IV. ZAP-70 was positive (>20%) in 50%, CD 38 was positive (>30%) in 33%, and CD49d was positive (>30%) in 49% of cases. Beta-2 microglobulin (B2M) was elevated (≥3.5 mg/L) in 80% of cases. Fifty five cases (50%, n = 110) were IGHV mutated. The mean number of cycles was 5 (1-6). Overall response rate (ORR) seen with BR was 90% and complete response was 45%. Median event free survival was 24 months with a median follow up period of 29 months. Haemoglobin ( Conclusions This is the first study of Asia to demonstrate safety and efficacy of BR in symptomatic CLL patients. BR is effective and safe regimen in the first-line treatment of CLL. Unmutaed- CLL patients have inferior EFS than mutated - CLL patients. Skin toxicity was the most common adverse effect seen in our population which was observed in around one third of cases. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest." @default.
• W2978889724 created "2019-10-10" @default.
• W2978889724 creator A5027030344 @default.
• W2978889724 creator A5041312321 @default.
• W2978889724 creator A5048526912 @default.
• W2978889724 creator A5049297652 @default.
• W2978889724 creator A5072952828 @default.
• W2978889724 creator A5074723032 @default.
• W2978889724 date "2019-10-01" @default.
• W2978889724 modified "2023-09-23" @default.
• W2978889724 title "Safety and efficacy of bendamustine and rituximab (BR) regimen in Indian chronic lymphocytic leukemia patients" @default.
• W2978889724 doi "https://doi.org/10.1093/annonc/mdz251.020" @default.
• W2978889724 hasPublicationYear "2019" @default.
• W2978889724 type Work @default.
• W2978889724 sameAs 2978889724 @default.
• W2978889724 citedByCount "0" @default.
• W2978889724 crossrefType "journal-article" @default.
• W2978889724 hasAuthorship W2978889724A5027030344 @default.
• W2978889724 hasAuthorship W2978889724A5041312321 @default.
• W2978889724 hasAuthorship W2978889724A5048526912 @default.
• W2978889724 hasAuthorship W2978889724A5049297652 @default.
• W2978889724 hasAuthorship W2978889724A5072952828 @default.
• W2978889724 hasAuthorship W2978889724A5074723032 @default.
• W2978889724 hasBestOaLocation W29788897241 @default.
• W2978889724 hasConcept C126322002 @default.
• W2978889724 hasConcept C143998085 @default.
• W2978889724 hasConcept C2777938653 @default.
• W2978889724 hasConcept C2778461978 @default.
• W2978889724 hasConcept C2779338263 @default.
• W2978889724 hasConcept C2780653079 @default.
• W2978889724 hasConcept C2781413609 @default.
• W2978889724 hasConcept C2781442060 @default.
• W2978889724 hasConcept C71924100 @default.
• W2978889724 hasConceptScore W2978889724C126322002 @default.
• W2978889724 hasConceptScore W2978889724C143998085 @default.
• W2978889724 hasConceptScore W2978889724C2777938653 @default.
• W2978889724 hasConceptScore W2978889724C2778461978 @default.
• W2978889724 hasConceptScore W2978889724C2779338263 @default.
• W2978889724 hasConceptScore W2978889724C2780653079 @default.
• W2978889724 hasConceptScore W2978889724C2781413609 @default.
• W2978889724 hasConceptScore W2978889724C2781442060 @default.
• W2978889724 hasConceptScore W2978889724C71924100 @default.
• W2978889724 hasLocation W29788897241 @default.
• W2978889724 hasOpenAccess W2978889724 @default.
• W2978889724 hasPrimaryLocation W29788897241 @default.
• W2978889724 hasRelatedWork W1696810722 @default.
• W2978889724 hasRelatedWork W1870216225 @default.
• W2978889724 hasRelatedWork W2012302440 @default.
• W2978889724 hasRelatedWork W2142682900 @default.
• W2978889724 hasRelatedWork W2165130809 @default.
• W2978889724 hasRelatedWork W2606155555 @default.
• W2978889724 hasRelatedWork W2781654484 @default.
• W2978889724 hasRelatedWork W2790101833 @default.
• W2978889724 hasRelatedWork W2791174505 @default.
• W2978889724 hasRelatedWork W2946591127 @default.
• W2978889724 hasVolume "30" @default.
• W2978889724 isParatext "false" @default.
• W2978889724 isRetracted "false" @default.
• W2978889724 magId "2978889724" @default.
• W2978889724 workType "article" @default.